Prime Highlights
- Elliott Investment Management sees significant margin expansion potential at Dexcom, calling it one of medtech’s strongest earnings growth stories.
- Expanded Medicare coverage for continuous glucose monitors, expected in 2027, could serve as a major upside catalyst for Dexcom.
Key Facts
- Dexcom is a US-based medical device company specialising in continuous glucose monitoring systems for diabetes management.
- Dexcom maintained its full-year revenue guidance between $5.16 billion and $5.25 billion despite beating quarterly Wall Street estimates last month.
Background
Medical device maker Dexcom has agreed to appoint two independent directors and restructure a key board committee following engagement with activist investor Elliott Investment Management.
Dexcom shares rose approximately 6% in after-hours trading after the announcement.
CEO Jake Leach said the company is actively refreshing its board and plans to bring in directors with medtech and operations expertise, an area where Dexcom currently lacks representation. The new appointments, to be announced at a later date, will take the total number of independent directors added since early 2023 to six.
The company also announced that its Technology Committee will be renamed the Operations and Innovation Committee. The revamped committee will carry an expanded mandate covering operations, quality oversight, and the company’s technical roadmap.
Elliott partner Marc Steinberg said the firm sees a clear path to significant margin expansion at Dexcom, calling it one of the most compelling earnings growth profiles in the medtech sector.
A separate development could further boost the company. The Centers for Medicare and Medicaid Services is weighing a decision on expanding Medicare coverage for continuous glucose monitors. Leach said Dexcom does not expect the change in 2026, viewing 2027 as the more likely timeline, though he noted an earlier rollout would be a positive development.
Last month, the company posted quarterly profit and revenue that beat Wall Street estimates. However, Dexcom maintained its full-year revenue guidance in the range of $5.16 billion to $5.25 billion.
